Edition:
India

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.62USD
19 Jan 2018
Change (% chg)

$0.18 (+2.13%)
Prev Close
$8.44
Open
$8.49
Day's High
$8.65
Day's Low
$8.28
Volume
145,098
Avg. Vol
420,564
52-wk High
$25.11
52-wk Low
$5.91

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $387.58
Shares Outstanding(Mil.): 36.22
Dividend: --
Yield (%): --

Financials

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

08 Jan 2018

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

12 Dec 2017

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

02 Nov 2017

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

30 Oct 2017

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

04 Oct 2017

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

25 Sep 2017

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

25 Sep 2017

BRIEF-NewLink Genetics Q2 loss per share $0.57

* NewLink Genetics - ‍expect to end 2017 with approximately $75 million in cash and equivalents, which excludes any cash that may be received from financing​

28 Jul 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,384 -6.50
Pfizer Inc. (PFE.N) $36.94 -0.05
Novartis AG (NOVN.S) CHF83.38 +0.48
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Abbott Laboratories (ABT.N) $59.31 +0.24
Sanofi SA (SASY.PA) €72.95 +0.58
AstraZeneca plc (AZN.L) 5,043.00 +62.50
GlaxoSmithKline plc (GSK.L) 1,358.00 +4.80

Earnings vs. Estimates